Rui Bernardino, MIS Clinical Fellow at Cleveland Clinic, shared on LinkedIn:
“Our multicentre review in Nature Reviews Urology explores the implications of intraductal carcinoma (IDC) and invasive cribriform carcinoma for prostate cancer risk stratification and treatment decisions.
Title: Cribriform and intraductal carcinoma in prostate cancer – implications for risk stratification and therapeutic decision-making
Authors: Rui M. Bernardino, João Lobo, Zeyad Schwen, Theodorus van der Kwast, Adam B. Weiner, Robert E. Reiter, Jane K. Nguyen, Estevão Lima, Robert Stein, Nicolas Soputro, Rashed Ghandour, Alp Tuna Beksac, Karim Daher, Ricardo Leão, Mark L. Gonzalgo, Roderick van den Bergh, Juan Garisto, Giancarlo Marra, Jennifer Le Guévelou Kammerer, Sara M. Falzarano, Cristina Magi-Galuzzi, Cosimo De Nunzio, Susan Prendeville, Neil Fleshner, Jihad Kaouk, Riccardo Autorino
These aggressive histological patterns are associated with adverse pathology, recurrence, metastasis and prostate cancer mortality. Yet they remain under-recognized and inconsistently reported.
Several key messages emerge:
- Detection remains a challenge: biopsy identifies these patterns in only about half of affected men, and MRI-targeted sampling does not fully close this gap.
- Their presence has important implications for patient selection for active surveillance and focal therapy.
- Their molecular features provide a rationale for investigating biomarker-directed treatments, but morphology alone does not establish benefit from a particular therapy.
Consistent pathology reporting, better detection and prospective studies are essential to translate these findings into more precise treatment decisions.”
You can also read:
FDA Fast Track Designation: BiPASS for Pre-Biopsy PSMA-PET Imaging in Prostate Cancer
